1,626 Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Acquired by Empowered Funds LLC

Empowered Funds LLC purchased a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,626 shares of the medical instruments supplier’s stock, valued at approximately $150,000.

Other large investors have also added to or reduced their stakes in the company. KBC Group NV grew its position in LeMaitre Vascular by 58.4% during the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after buying an additional 410 shares in the last quarter. SG Americas Securities LLC acquired a new stake in LeMaitre Vascular during the fourth quarter worth approximately $158,000. Advisors Asset Management Inc. grew its position in LeMaitre Vascular by 180.2% during the third quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier’s stock worth $172,000 after buying an additional 1,191 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in LeMaitre Vascular during the third quarter worth approximately $181,000. Finally, James Investment Research Inc. acquired a new stake in LeMaitre Vascular during the third quarter worth approximately $201,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

Wall Street Analyst Weigh In

LMAT has been the topic of a number of analyst reports. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a report on Friday, November 1st. Barrington Research raised their target price on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Finally, Wells Fargo & Company initiated coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price on the stock. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and a consensus price target of $94.63.

LeMaitre Vascular Stock Performance

Shares of LMAT opened at $99.63 on Friday. LeMaitre Vascular, Inc. has a 52 week low of $59.87 and a 52 week high of $109.58. The stock has a market capitalization of $2.24 billion, a price-to-earnings ratio of 54.44, a PEG ratio of 2.22 and a beta of 0.96. The stock has a fifty day moving average of $96.03 and a 200-day moving average of $94.19.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.